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The importance of improving HLA matching for African-
American recipients is frequently stressed in discussions of 
cadaver kidney allocation. The argument has been that such 
efforts will be especially important for improvement of graft 
survival of African-Americans who have had poorer results 
than members of all other subgroups. In reality, data sup-
porting this assumption are conflicting except when there is 
a zero mismatch (1-6). 
The opportunity to obtain clarifying information presented 
itself during performance of a recent multivariate analysis of 
31,291 cases of primary cadaver kidney transplantation re-
ported to the United Network for Organ Sharing (UNOS*) 
Scientific Registry between 1991 and 1995 (7), for which 
follow-up was to January 1, 1997. The collection included 
8,111 African-Americans, whose graft survival at all grada-
tions of HLA mismatch level is presented herein. The Pitts-
burgh experience was excluded because tacrolimus was rou-
tinely given to those patients during the period of the 5-year 
case accrual. Nevertheless, 3.2% of the patients at other 
UNOS centers were treated with this drug (2.5% of the 8,111 
African-Americans and 3.4% of the 23,180 "all others"). The 
remaining 96.8% had cyclosporine-based therapy. 
Donor and recipient serologic typing of the HLA-A, -B, and 
-DR loci was routinely obtained throughout the period of 
study. The degree of incompatibility was expressed in each 
case as zero to six HLA mismatches. It has been reported (8) 
and was confirmed herein (data not shown) that such results 
accurately reflect the compatibility expressed by the six-to-
zero HLA match scale. As reported in detail elsewhere (7), 
the relationship between the level of HLA mismatch and rate 
of graft survival was assessed with Cox proportional hazards 
regression modeling (program 2L of the BMDP package [9]). 
Half-lives for kidneys still surviving at 1 year were estimated 
with both with the Cox regression method (see [7]) and with 
the conventional method that takes into account only actual 
data from 1 year onward (10). In Figure 1, the results with 
the latter method are given in parentheses. 
Only 174 (2.1%) ofthe 8,111 African-Americans received a 
zero mismatched kidney, compared with 9.9% in the 23,180 
"all other" population (Table 1). At the other end of the 
I This work was supported by project grant DK 29961 from the 
National Institutes of Health. Bethesda. MD. 
2 Thomas E. Starzl Transplantation Institute. University of Pitts-
burgh Medical Center. 
3 Address correspondence to: Velma Scantlebury. MD. Thomas E. 
Starzl Transplantation Institute. 3601 Fifth Avenue. 4C Falk Clinic. 
Pittsburgh, PA 15213. 
4 UCLA Tissue Typing Laboratory, UCLA School of Medicine. 
S Department of Epidemiology and Biostatistics. UniversIty of 
Western Ontario. 
• AbbreViations: CREG. cross-reactive antigen group; UNOS. 
United Network for Organ Sharing. 
matching scale, an additional 558 African-Americans (6.9%) 
received a six-antigen (full-house) mismatch. Thus, 91.2% of 
the African-American recipients were in the one-to-five mis-
match spectrum, which also bracketed more than 85% of the 
"all other" cases (Table 1). 
The graft survival in African-Americans at the I-year post-
transplant milestone was not markedly lower than that of 
the "all other" population at any of the HLA mismatch levels. 
More relevant to the primary objective of this study, only a 
zero mismatch conferred a major benefit (Table 2). One year 
allograft survival from the top to the bottom of the one-to-five 
HLA mismatch range varied by less than 2% (Table 2). The 
lack of a stepwise effect also was evident in the one-to-five 
mismatch range of the "all other" population, where the 
I-year survival did not vary by as much as 3% (Table 2). 
By 3 years, graft survival in African-Americans had be-
come inferior to that of "all others" (Table 2). However, be-
cause survival declined by approximately 10% at every level 
of HLA compatibility, including zero mismatches, the differ-
ence in 3-year graft survival all the way from one to five 
mismatches was only 2.4%, with reversal in order of the four 
and five HLA mismatched tiers. The pattern of results in the 
"all other" recipient population (Table 2) was essentially the 
same. 
Between 1 and 3 years, there was very little divergence of 
survival in the various categories of HLA mismatch within 
the African-American population. Instead, the principal and 
relatively minor separation of curves had already occurred by 
the end of the first year at all levels of HLA mismatch (Table 
2). Although the percentages were slightly different in the 
23,180 "all other" cases, the graded HLA effect also was 
modest. Of interest, when half-lives were calculated using 
only actual data from 1 year onward (as opposed to the Cox 
regression prediction), the half-lives of zero mismatched kid-
neys in African-American recipients were the same as those 
with two to six mismatches (Fig. 1), which is different than in 
the "all other" population. 
In Figure 1, the hazard ratio (or relative risk) over the first 
3 years with various degrees of mismatch in African-Ameri-
cans (left) or in all others (right) was calculated using the 
zero HLA mismatch as the reference standard of 1.0. The 
principal adverse effect came with the first mismatch, which 
for the African-Americans increased the relative risk of graft 
loss within 3 years to a modest 1.2 years. However. the 
relative risk only increased further to 1.3 years all the way 
from one to five mismatches. For the "all other" population 
(Fig. 1, right), the relative risk between one and five mis-
matches rose from l.2 to 1.5. 
UNOS has promoted trials of matching cross-reactive an-
tigen groups (the so-called CREGs or public determinants) 
with the contention that this can be more discriminating as 
e 
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well as more equitable than conventional HLA matching for 
African-Americans (11, 12). We have reported elsewhere on 
the CREG match effect in the 31,291 UNOS cases (7), using 
the computer program of Takemoto et al. (11) to convert the 
conventional HLA phenotypes to CREGs. The results (see [7] 
for details) suggested that CREG-matched patients (particu-
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FIGURE 1. Graft survival and calculations of hazard ratios (HR 
equivalent to relative risk) over the first 3 posttransplant years, 
based on number of HLA mismatches and of African-American 
(n=8111) and all other primary cadaver kidney recipients reported 
to the UNOS Scientific Registry 0991-1995). The reference hazard 
ratio (1.0) was provided by zero mismatch cases. Half-lives (HL) 
calculated with Cox regression analysis are shown side by side with 
those calculated by the conventional method (10), which are in pa-
rentheses. 
TABLE 1. Distribution of HLA mismatchesa 
African-Americans 
174(2.1%) 
206 (2.5%) 
783 (9.7%) 
2037 (25.1%) 
2665 (32.90/0) 
1688 (20.8%) 
558 (6.9%) 
HLA mismatches 
o 
1 
2 
3 
4 
5 
6 
All others 
2286 (9.9%) 
1128 (4.9%) 
3225 (13.9%) 
6034 (26.00/0) 
5877 (25.3%) 
3509 (15.1%) 
1211 (4.8%) 
a Bold type constitutes 91.2% of African-American recipients and 
85.3% of all others. 
TABLE 2. % graft survival at 1 and 3 years" 
African-Amencans HLA mismatches All others In=S.llll In=23,lSOl 
87.1 (73.41 0 89.2 (82.3) 
84.6 (68.7) 1 86.9 (78.7) 
84.3 (68.2) 2 86.4 (77.9) 
83.9 (67.5) 3 86.2 (77.6) 
83.0 (65.9) 4 84.5 (75.0> 
83.3 (66.3) 5 84.0 (74.3) 
81.5 (63.21 6 83.0 (72.9) 
., Bold type constitutes 91.2'1- of African-American recipients and 
85.3'1- of all others. Numbers in parentheses indicate 3-year survival 
rate \ (fl. 
TABLE 3. CREG matched cases (31,291)" 
HLA mismatch 
0 
1 
2 
3 
4 
5 
6 
CREG 
match/mismatch 
2460/2460 
47111334 
41614008 
20618071 
5718542 
0/5197 
0/1679 
% 
100 
35.3 
10.4 
2.6 
0.7 
o 
o 
a Bold type indicates HLA-defined tiers in which 91.2% of African-
American and 85.3% of all other recipients are placed (UNOS 1991-
1995). The CREG match yield was 1150 (3.6%). 
TABLE 4. CREG-matched cases in different HLA mismatch tiers 
African-American 
1741174 (100%) 
811206 (39.3%) 
17215485 (3.1%) 
012246 (0%) 
25317937 (3.2%)" 
HLA mismatches 
o 
1 
2-4 
5,6 
All others 
228612286000%) 
390/1128 (34.6%) 
507/15136 (3.3%) 
0/6034 (0%) 
897/20894 (4.3%)" 
a CREG match yield other than zero HLA matches. 
larly in African-Americans), who have only one HLA mis-
match, may have a higher graft survival at 3 years than 
CREG-mismatched patients at this HLA tier. This was not 
true of CREG matches culled from two to four HLA incom-
patibility tiers (7). 
Any enthusiasm generated by the CREG match findings in 
the 1-HLA mismatch category is dampened by an assessment 
of the distribution profile (Table 3). Because CREG matching 
is directly derived from HLA phenotypes, the 2460 zero HLA 
mismatched UNOS cases were by definition also CREG 
matched (a 100% yield). With the succession from one to four 
HLA mismatches, the CREG match yield fell to 35%, 10%, 
2.5%, and less than 1 % in these respective tiers. There were 
no CREG matches in the five and six HLA mismatch catego-
ries. The overall yield of CREG matches from the one to five 
HLA populations in which 90% of the UNOS recipients fell 
was only 3.6%. These CREG-matched organs went to only 
3.2% of the 7,937 African-Americans who did not get a zero 
HLA mismatched kidney and to 4.3% of the comparable 
20,894 "all others" (Table 4). 
In conclusion, HLA matching except when there is zero 
HLA-A, -B, and -DR incompatibility has had even less influ-
ence on short or long term primary cadaver kidney survival 
in African-Americans than the minimal effect in the non-
African-American population. 
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Background. The Rh (D) blood group system has not 
traditionally been considered to be a clinically rele-
vant histocompatibility barrier in transplantation 
since conflicting results of its clinical importance have 
been reported. 
Methods. We analyzed 786 consecutive primary ca-
daveric renal transplants performed by transplant 
centers in our Organ Procurement Organization 
(OPO) between 1990 and 1997. We also analyzed United 
Network for Organ Sharing (UNOS) data on 26,469 
kidney transplants done from April 1994 to June 1996. 
Results. Multivariate analysis revealed that Rh iden-
tity between the recipient and donor was significantly 
related to better graft outcome (risk ratio, 0.43; 95% 
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confidence interval, 0.30 to 0.61; P=O.OOOl). Multivari-
ate analysis of the UNOS data revealed that the Rh -/-
group may have a positive influence on graft survival 
with a risk ratio of 0.43 (P=O.14). 
Conclusion. Multivariate analysis of primary cadav-
eric renal allografts performed within the Midwest 
Organ Bank OPO indicates that Rh (D) is a clinically 
relevant histocompatibility barrier that influences 
7-year graft survival. 
The Rh (D) blood group system is not thought to be a 
clinically relevant histocompatibility barrier to transplanta-
tion because, unlike the ABO system (1), Rh is not thought to 
be expressed on the endothelium. However, Rh has been 
shown to be expressed on kidney homogenates at levels 
equivalent to A and B antigens (2). Conflicting reports of the 
clinical relevance of Rh on graft outcome were published in 
the 1970s (3-5) and in 1988 (6); however, major changes in 
immunosuppression have occurred since these studies were 
performed. 
We examined the clinical relevance of Rh nonidentity in 
renal transplantation and were startled with the results of 
our mutlivariate and univariate analyses, which uniformly 
showed that Rh nonidentity had a detrimental influence on 
graft survival among our primary cadaveric renal allograft 
recipients. We then analyzed the influence ofRh in national 
• 
